Glòria Merino Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Glòria Merino Pinto has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ana María Linas-Alonso
Department of Cardiology, Hospital del Mar, Spain
1 shared publication - Antoni Gilabert-Perramon
Department of Pharmaceutical Care and Complementary Benefits, Catalan Health Service, Government of Catalonia, Barcelona, Spain
1 shared publication - Arlet Puigferrat Campderrós
Centre de Recerca en Economia de la Salut (CRES), Universitat Pompeu Fabra (UPF), Barcelona, Spain, Spain
1 shared publication - Concepción Gómez-Gavara
HPB Surgery and Transplants Department Hospital Universitari Vall D'hebron Barcelona Spain
1 shared publication - Edson Plasencia Sánchez
SIMBIOsys Group, Department of Engineering, Universitat Pompeu Fabra, Carrer de Tanger 122, Barcelona, 08018, Spain
1 shared publication - Francesc López Seguí
Department of Epidemiology and Evaluation, Hospital del Mar, Barcelona, Catalonia; Center for Research in Health and Economics, Pompeu Fabra University, Barcelona, Catalonia; Chair in ICT and Health, Centre for Health and Social Care Research (CESS), University of Vic-Central University of Catalonia (UVic-UCC), Vic, Catalonia
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1)
The Spanish transplantation model as a benchmark: clinical, societal, and economic impact of liver transplants in Spain (1984–2024)
Spain leads the world in organ donation, and the 40th anniversary of its first liver transplant was recently commemorated. Our aim was to evaluate the evolution of the Liver Transplantation (LT) program in Spain over its four decades (1984–2024), examining clinical outcomes and societal economic benefits within a mature transplantation framework. Standardized national data from the Organización Nacional de Trasplantes and the Sociedad Española de Trasplante Hepático were used to reconstruct recipient cohorts by age group. Patient survival was estimated using Kaplan–Meier analysis. An economic evaluation from a societal perspective integrated surgical costs, long-term immunosuppressive therapy, and productivity gains associated with recipients’ participation in the labour market. LT activity increased steadily during the initial expansion of the program and has stabilised at approximately 1,200 procedures per year over the past two decades. Both donor and recipient populations have aged; there are currently more patients over 60 years of age than two decades ago. Survival improved throughout the study period, extending life expectancy despite variations related to underlying disease. From an economic perspective, annual surgical costs remained below €60 million, increasing to €70–90 million when long-term immunosuppressive therapy was included. The economic contribution of surviving recipients to the labour market increased steadily, exceeding €75 million in 2024 and resulting in a positive balance since the early 2010s. Adult recipients generated net economic benefits, whereas paediatric recipients showed delayed but progressively increasing contributions as they entered the workforce. LT in Spain has produced sustained improvements in expected survival while generating substantial societal value, demonstrating that LT is both an effective clinical intervention and a valuable public health investment. The Spanish liver transplantation system may serve as a benchmark for evaluating the sustainability and societal impact of liver transplant programs in other healthcare systems.
- 2 June 2026
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1)
Open AccessThe Spanish transplantation model as a benchmark: clinical, societal, and economic impact of liver transplants in Spain (1984–2024)
Spain leads the world in organ donation, and the 40th anniversary of its first liver transplant was recently commemorated. Our aim was to evaluate the evolution of the Liver Transplantation (LT) program in Spain over its four decades (1984–2024), examining clinical outcomes and societal economic benefits within a mature transplantation framework. Standardized national data from the Organización Nacional de Trasplantes and the Sociedad Española de Trasplante Hepático were used to reconstruct recipient cohorts by age group. Patient survival was estimated using Kaplan–Meier analysis. An economic evaluation from a societal perspective integrated surgical costs, long-term immunosuppressive therapy, and productivity gains associated with recipients’ participation in the labour market. LT activity increased steadily during the initial expansion of the program and has stabilised at approximately 1,200 procedures per year over the past two decades. Both donor and recipient populations have aged; there are currently more patients over 60 years of age than two decades ago. Survival improved throughout the study period, extending life expectancy despite variations related to underlying disease. From an economic perspective, annual surgical costs remained below €60 million, increasing to €70–90 million when long-term immunosuppressive therapy was included. The economic contribution of surviving recipients to the labour market increased steadily, exceeding €75 million in 2024 and resulting in a positive balance since the early 2010s. Adult recipients generated net economic benefits, whereas paediatric recipients showed delayed but progressively increasing contributions as they entered the workforce. LT in Spain has produced sustained improvements in expected survival while generating substantial societal value, demonstrating that LT is both an effective clinical intervention and a valuable public health investment. The Spanish liver transplantation system may serve as a benchmark for evaluating the sustainability and societal impact of liver transplant programs in other healthcare systems.
- Open Access
- 27 February 2026
- Published by MDPI AG in Preprints.org
Cost-Effectiveness of a Nurse-Led Telemedicine-Based Program for Patients with Heart Failure: The MAR-HF-Titration Study
This study evaluates the cost-effectiveness of the MAR-HF-Titration telemedicine programme, implemented at Hospital del Mar for patients with heart failure with reduced ejection fraction (HFrEF). A pre-post retrospective cost-effectiveness analysis was conducted using data from 208 patients enrolled between 2021 and 2023. Effectiveness was estimated by constructing individual pre- and post-intervention QALYs based on literature-derived utility values. Cost data were obtained from hospital administrative records at the patient level. Paired t-tests were performed, and costs and QALYs were modelled using gamma and beta distributions for probabilistic sensitivity analysis. A sensitivity analysis excluding newly diagnosed patients was also conducted. The programme was associated with a 52% reduction in total healthcare costs (€4,771.79 per patient), mainly driven by a reduction of the heart failure-related intervention costs, which accounted for 88% of total costs and decreased by 58% in the post-intervention period (€4,384.97 per patient). This reduction was also associated with a substantial decrease in length of stay during the post-intervention period, with a 76.63% reduction in total hospitalisations and an 82.34% reduction in hospitalisations related to heart failure. The effectiveness analysis showed an increase of 0.0298 QALYs per patient during the six-month intervention period. Similar outcomes were observed for non-newly diagnosed patients.
- 27 February 2026
- Published by MDPI AG in Preprints.org
Open AccessCost-Effectiveness of a Nurse-Led Telemedicine-Based Program for Patients with Heart Failure: The MAR-HF-Titration Study
This study evaluates the cost-effectiveness of the MAR-HF-Titration telemedicine programme, implemented at Hospital del Mar for patients with heart failure with reduced ejection fraction (HFrEF). A pre-post retrospective cost-effectiveness analysis was conducted using data from 208 patients enrolled between 2021 and 2023. Effectiveness was estimated by constructing individual pre- and post-intervention QALYs based on literature-derived utility values. Cost data were obtained from hospital administrative records at the patient level. Paired t-tests were performed, and costs and QALYs were modelled using gamma and beta distributions for probabilistic sensitivity analysis. A sensitivity analysis excluding newly diagnosed patients was also conducted. The programme was associated with a 52% reduction in total healthcare costs (€4,771.79 per patient), mainly driven by a reduction of the heart failure-related intervention costs, which accounted for 88% of total costs and decreased by 58% in the post-intervention period (€4,384.97 per patient). This reduction was also associated with a substantial decrease in length of stay during the post-intervention period, with a 76.63% reduction in total hospitalisations and an 82.34% reduction in hospitalisations related to heart failure. The effectiveness analysis showed an increase of 0.0298 QALYs per patient during the six-month intervention period. Similar outcomes were observed for non-newly diagnosed patients.